skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Peter and His Wonder Team
I realize shipping stocks are cyclical...Not sure if the wars or new supply chains are a positive or negative. What I mean is they could charge higher rates if there is risk involved. In any event I have held this stock for too many years and am even. However at this point it appears to be "dead-money"...if you know what I mean. Can you see any reason to be patient for a few more quarters? Thanks as always...your opinion is always a voice of reason!
Read Answer Asked by Ernest on January 05, 2024
Q: What are your current thoughts on KEYS? I'm up 55% and thinking of buying some more, maybe increase my overall weighting to 5%. The latest numbers seem positive and I like that they are getting involved on EV battery testing and charging. EV battery charging seems to be a problem if you don't drive a Tesla. Probably would need to sell some NVDA to raise the USD which is not ideal but of course our NVDA weighting is too high. Also is KEYS an Industrial Company? Any thoughts you have would be appreciated.
Jim
Read Answer Asked by James on January 05, 2024
Q: Your thoughts on this company? Is it a buy, sell or hold?
Read Answer Asked by Charles on January 04, 2024
Q: Please provide your comments on the risk for the above ETFs (low to high) and rank them for potential growth. Are there Canadian equivalents to the US ETFs? Would it be a good idea to purchase the US ETFs in a TFSA? Would these ETFs currently be considered to be a buy, hold or sell?
Thank you
Read Answer Asked by Don on January 04, 2024
Q: Basket defense stocks: could you suggest a basket of defense stocks for 3+ year hold. A short comment on why you like them would be appreciated.
Thanks
Read Answer Asked by sam on January 04, 2024
Q: I am puzzled by the sudden rise in AMGN share price today. The only news I see is from a week ago, that the FDA completed a report on the Lung Cancer drug Lumakras, voting *against* full approval. The drug was conditionally approved in May 2021, and I believe the condition was that Amgen had to complete a comparative trial, showing it was more effective than other treatments like chemotherapy, in order to receive full approval. But it sounds like their trial failed due to dropouts from their "other treatment" group.
Why would this "rejection" result in a sudden rise in share price? Or is it due to something else, like a broker upgrade?
Read Answer Asked by Ed on January 04, 2024
Q: ROKU had a great 2023. Towards year end, it was hit with a couple of downgrades. 5i continues to like it, in response to Q&As. Could you please list the top 2-3 reasons you have for ROKU to have another good year(s). I am not expecting it to duplicate its 2023 success, but looking to quantify whether ROKU has several more years of growth.
Read Answer Asked by Greg on January 04, 2024
Q: Hi Peter and Staff
No rush ... Happy New Year......just watched a BNN Market Call and guest tried to justify decline in his past pick JNJ by saying the numbers do not include the spinout (Kemba)? ........I held JNJ through that spin out period and never received any of the spinout. It would seem logical the price would drop after a spin out but how does that affect those who never got the spinout?

Thanks for all you do
Dennis
Read Answer Asked by Dennis on January 03, 2024
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!